Rare case report on Acitrom induced coagulopathy with seizure disorder
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252431Keywords:
Coagulopathy, Seizures, Thrombotic riskAbstract
Acitrom (nicoumalone), a vitamin K antagonist, is widely used for the prevention of thromboembolic disorders. However, its narrow therapeutic index mandates vigilant monitoring to avoid complications like coagulopathy. This case report presents a 59-year-old female with a history of cerebral venous thrombosis, coronary artery disease, and seizures who developed Acitrom-induced coagulopathy. She was admitted with symptoms of headache, vomiting, burning sensation in the lower limbs, and later with bleeding from the gums and oral cavity, melena, and a generalized tonic-clonic seizure. Her past medication included Acitrom, Thyroxin, Atorvastatin, Aspirin, and several other supportive drugs. Investigations revealed deranged coagulation parameters, with INR elevated beyond the therapeutic range. MRI and MRV indicated partial recanalization of cerebral venous sinuses, with no evidence of infarction or hemorrhage. She was managed with intravenous vitamin K, fresh frozen plasma, and antiepileptics including phenytoin and levetiracetam. The offending agent, Acitrom, was discontinued. The patient responded well to treatment and was discharged on antiepileptic and supportive therapy. This case emphasizes the importance of close INR monitoring and patient education to identify early signs of bleeding. Seizure in the context of anticoagulant-induced coagulopathy is rare and requires immediate attention. Interdisciplinary collaboration among neurology, internal medicine, and hematology is critical for optimizing patient outcomes. Early recognition, timely reversal of anticoagulation, and individualized care can significantly reduce morbidity in such complex clinical presentations.
Metrics
References
Carcas AJ, Borobia AM, Velasco M, Abad- Santos F, Díaz MQ, FernándezCapitán C, et al. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: Study protocol for a randomized controlled trial. Trials. 2012;13(2):239. DOI: https://doi.org/10.1186/1745-6215-13-239
Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ. 2002;325:1073–5. DOI: https://doi.org/10.1136/bmj.325.7372.1073
Dentali F, Ageno W. Treatment of coumarin-associated Coagulopathy: a systematic review and proposed treatment algorithms Journal of Thrombosis and Haemostasis, 2006;4:1853–63. DOI: https://doi.org/10.1111/j.1538-7836.2006.01986.x
Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hämostaseologie. 2021;41(02):104-10. DOI: https://doi.org/10.1055/a-1384-3715
Lüscher TF, Davies A, Beer JH, Valgimigli M, Nienaber CA, Camm JA, et al. Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. European Heart J. 2022;43(10):940-58. DOI: https://doi.org/10.1093/eurheartj/ehab642
Rosand J Eckman MH Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;7:76. DOI: https://doi.org/10.1001/archinte.164.8.880
Kirshner H, Schrag M. Management of intracerebral hemorrhage: update and future therapies. Current Neurol Neurosci Rep. 2021;21:1-5. DOI: https://doi.org/10.1007/s11910-021-01144-9
Hankins GD, Koen S, Gei AF, Lopez SM, Van Hook JW, Anderson GD. Neonatal organ system injury in acute birth asphyxia sufficient to result in neonatal encephalopathy. Obstet Gynecol. 2002;99(1):688–91. DOI: https://doi.org/10.1097/00006250-200205000-00004
Cendes F, Theodore WH, Brinkmann BH, Sulc V, Cascino GD. Neuroimaging of epilepsy. Handbook of clinical neurology. 2016;136:985-1014. DOI: https://doi.org/10.1016/B978-0-444-53486-6.00051-X
Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41(7):965-8. DOI: https://doi.org/10.1212/WNL.41.7.965
11. Roberts MA, Godfrey JW. Epileptic seizures in the elderly. I. Aetiology and type of seizure. Age and Ageing. 1982;11:24–8. DOI: https://doi.org/10.1093/ageing/11.1.24
Myint PK, Staufenberg EFA, Sabanathan K. Post-stroke seizure and post-stroke epilepsy. Postgraduate Medical Journal 2006;82:568– 72. DOI: https://doi.org/10.1136/pgmj.2005.041426
Nakken KO, Refsland G, Lillestølen KM, Solaas MH. Seizure-precipitating factors in epilepsy-- what do patients report. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2005;125(16):2172-4.
14. Sánchez S, Rincon F. Status epilepticus: epidemiology and public health needs. J Clin Med. 2016;5(8):71. DOI: https://doi.org/10.3390/jcm5080071
Alvarez V, Rossetti AO. Clinical Consequences of Generalized Convulsive Status Epilepticus. Status Epilepticus: A Clinical Perspective. 2018:111-21. DOI: https://doi.org/10.1007/978-3-319-58200-9_9
Neuenfeldt FS, Weigand MA, Fischer D. Coagulopathies in intensive care medicine: balancing act between thrombosis and bleeding. J Clin Med. 2021;10(22):5369. DOI: https://doi.org/10.3390/jcm10225369